Welcome to our dedicated page for Aslan Pharms news (Ticker: ASLN), a resource for investors and traders seeking the latest updates and insights on Aslan Pharms stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aslan Pharms's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aslan Pharms's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ASLAN Pharmaceuticals (NASDAQ: ASLN) announced acceptance of two late-breaking abstracts for the 1st International Societies for Investigative Dermatology (ISID) Meeting in Tokyo from May 10-13, 2023. One abstract focuses on eblasakimab and its effects in atopic dermatitis (AD), while the other highlights farudodstat in alopecia areata. Published data show that eblasakimab significantly improves Eczema Area and Severity Index (EASI) scores, particularly in sensitive areas. The treatment also inhibits neuronal sensitization to itch, potentially offering broad therapeutic benefits. Results from the Phase 2 TREK-AD study are expected in early July 2023, while an upcoming proof-of-concept trial for farudodstat is planned for Q2 2023.
ASLAN Pharmaceuticals (Nasdaq: ASLN) announced that it has regained compliance with Nasdaq's minimum bid price requirement, with a closing bid price above $1.00 for 10 consecutive business days, as of March 27, 2023. This follows a previous notice from Nasdaq on March 28, 2022, regarding non-compliance due to the bid price dropping below $1.00. The company develops innovative treatments, including eblasakimab for atopic dermatitis and farudodstat for alopecia areata, with ongoing clinical trials. ASLN's continued listing on Nasdaq is contingent upon meeting all applicable standards moving forward.
ASLAN Pharmaceuticals (Nasdaq: ASLN) has announced its financial results for Q4 and full year 2022, reporting a net loss of $51.4 million compared to $31.3 million in 2021. The increase in loss is primarily due to elevated research and development expenses of $38.0 million, driven by clinical development costs for eblasakimab. The company has successfully enrolled patients in its TREK-AD Phase 2b trial and expects topline data by early July 2023. Following a recent $20 million financing, ASLAN anticipates its cash runway extended through Q2 2024. Additionally, a Phase 2 trial for farudodstat in alopecia areata is set to begin in Q2 2023, with data expected in Q1 2024.